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Introduction
Antepartum amnioinfusion is a procedure under de-
bate. Some authors claim that it can reduce the rate of
pulmonary hypoplasia, which is one of the main deadly
sequelae of oligohydramnios [1,2]. However, its safety
worries others, especially the theoretical fear of the
complications related to invasive procedures such as
infection, fetal loss, and even amniotic fluid embolism
[3]. A large randomized trial is lacking despite several
large-scale case-control studies revealing that it seems
to provide benefit to the fetus, no matter whether the
amniotic membranes are intact or ruptured, and does
not induce more complications than conservative treat-
ment [2–4].
The overall perinatal mortality after previable
preterm premature rupture of membranes (PPROM),
if managed expectantly, is about 60%, regardless of
whether it is iatrogenic or spontaneous [5,6]. Several
SUMMARY
Objective: To evaluate the efficacy and safety of aggressive management of oligohydramnios.
Methods: Forty women with oligohydramnios (< 30 complete weeks), either because of preterm premature
rupture of membranes or with intact membranes, were prospectively enrolled in this study. Eleven women were
assigned to the treatment group and 29 to the control group. Transabdominal amnioinfusion was performed
with warm Ringer’s lactate or normal saline in all 11 patients in the treatment group. In addition, cerclage
was performed in patients with ruptured amniotic membranes. Amniopatch was used to salvage a patient
with immediate amniorrhea (< 6 hours) after the above procedures.
Results: Nine of the 11 patients prolonged their pregnancy for at least 3 weeks (81.8%), while all 29 patients
in the control group delivered their babies within 3 weeks of diagnosis of oligohydramnios (p < 0.05). Signs
of maternal infection were noted in two patients in the treatment group (18.2%). The newborns of eight patients
in the treatment group survived beyond 1 month (72.7%), whereas this occurred in only six control patients
(20.7%; p < 0.05).
Conclusion: Aggressive management seemed to provide prolongation of pregnancy compared with no treat-
ment. Amniopatch salvaged the immediate amniorrhea in our patient. [Taiwanese J Obstet Gynecol 2005;44(4):
347–352]
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experimental therapies have been proposed to treat
PPROM. Serial amnioinfusion or maternal adminis-
tration of vasopressin to induce fetal diuresis has been
used to restore amniotic fluid volume [7,8]. However,
the resulting amniorrhea often makes the effort point-
less. Fetoscopic closure of the defect (amniograft) [9],
occlusion of the cervical canal with fibrin glue [10,11],
in situ cerclage [12], and instillation of platelets fol-
lowed by cryoprecipitation (amniopatch) [13] were de-
vised to tackle the condition. Among these treatments,
amniopatch appeared to be promising in the two small
series reported to date in iatrogenic PPROM caused by
genetic invasive diagnostic procedures or by fetoscopic
intervention [13,14].
Here, we present our experience of managing oligo-
hydramnios without concomitant intrauterine infection
using various treatment modalities including antepar-
tum amnioinfusion (to treat oligohydramnios without
PPROM), antepartum amnioinfusion with or without
cerclage (for oligohydramnios with PPROM), and
successful allogenic amniopatch to salvage a woman
with oligohydramnios caused by spontaneous PPROM
who suffered from amniorrhea after amnioinfusion
together with emergency cerclage. This was a valuable
success since amniopatch appears less effective in
women with spontaneous PPROM [13,14].
Methods
Patients and selection criteria
Eleven patients with oligohydramnios (amniotic fluid
index, AFI, ) 5), singleton pregnancy, and normal karyo-
type at less than 30 complete gestational weeks were
recruited at National Taiwan University Hospital and
Changhua Christian Hospital for aggressive manage-
ment after informed consent was obtained with auto-
nomy under the care of the same physician (M. Chen)
between October 2002 and May 2005. Enrollment was
simultaneous at the two hospitals, both of which are
tertiary referral medical centers. Status of amniotic
membranes (intact or ruptured), gestational age, and
ethnic background were carefully examined and clas-
sified. Karyotyping was performed by mid-trimester
chorionic villus sampling (CVS), small-amount
amniocentesis, or cordocentesis. Another 29 similar
patients who received expectant and conservative
treatment were prospectively enrolled as the control
group in 2003–2005 at the same two hospitals. Para-
meters including maternal age, gestational age at
diagnosis, and the percentage of PPROM were match-
controlled. All patients received prophylactic oral anti-
biotic therapy.
Exclusion criteria
We excluded women who were in active labor or had
fever (maternal temperature > 38°C), maternal leuko-
cytosis (white blood cell count > 15,000/mL), a history
of cervical incompetence, cervical length less than 4
cm by ultrasound at the time of diagnosis of oligohy-
dramnios, or maternal/placental problems including
hyperthyroidism, pregnancy-induced hypertension,
gestational diabetes, or placental tumors. Patients
whose fetuses had bilateral renal agenesis, obstructive
uropathy, or multiple anomalies at the time of diagnosis
of oligohydramnios, despite most of them undergoing
one-time amnioinfusion to facilitate ultrasound diag-
nosis, were not included. In other words, we only enrolled
women with oligohydramnios caused by PPROM or
idiopathic oligohydramnios with the amniotic mem-
branes intact, to study the efficacy of amnioinfusion
without interference from confounding factors in the
fetuses or mothers.
Interventions
For amnioinfusion, varying amounts (200–500 mL) of
warm, sterile Ringer’s lactate or normal saline were
slowly infused through an intravenous set originally
designed for blood transfusion after the conduit was
established with a 21-gauge spinal needle inserted
into the amniotic cavity with the assistance of real-
time ultrasound (Voluson® 730, GE Medical Systems,
Milwaukee, WI, USA). Patients were prescribed anti-
biotics and tocolytics to prevent maternal infection and
preterm delivery before and after the invasive procedure.
Patients were admitted for at least 24 hours’ hospitali-
zation to observe the immediate postoperative condition.
In cerclage, the McDonald approach was used in
patients with oligohydramnios caused by ruptured
membranes who showed no signs of infection before
amnioinfusion.
Amniopatch was performed according to the pro-
tocol devised by Quintero et al [13]: 100 mL warm nor-
mal saline was infused intra-amniotically under ultra-
sound monitoring without knowing the exact site
of rupture of the amniotic membranes. Cross-matched
allogenic platelets (0.5 units) were then infused, fol-
lowed by 0.5 units cryoprecipitate. Another 100 mL
warm normal saline was then instilled to achieve the
optimal deepest pocket of the amniotic fluid bag, that
is, about 5 cm of the maximal vertical pool depth in
our patient.
Elective cesarean section was chosen by all women
who wished to save the fetus at delivery.
Data
Maternal age, ethnic background, gestational age at
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onset of oligohydramnios, gestational age at delivery,
latency period between diagnosis and delivery, number
of serial amnioinfusions, rate of PPROM, neonatal
survival, rate of cesarean delivery, rate of intrauterine
fetal demise, number of patients whose latency period
was more than 21 days, birth body weight, number of
patients who underwent termination of pregnancy
(TOP) of the viable fetus, number of patients who de-
veloped fever or leukocytosis after onset, and karyotype
were carefully reviewed and tabulated. Pathology reports
for the delivered placenta as well as dead fetuses were
recorded, if available.
Statistical analysis
Fisher’s exact test and two-tailed Student’s t test
were used to analyze relevant data using STATA (Stata
Corp, College Park, TX, USA) and Microsoft Excel soft-
ware.
Results
Seven of 11 women (63.6%) in the treatment group and
20 of the 29 control women (69.0%) were Taiwanese/
Chinese; the remaining subjects were women from
Vietnam, Cambodia, or the Philippines married to a Tai-
wanese husband. Four women in the treatment group
(36.4%) and 13 control women (44.8%) had PPROM
(Table 1). There was no significant difference between
the groups in maternal age (32 vs 33 years), gestational
age at diagnosis (23 vs 23 weeks), and the percentage of
PPROM. Seven women who had intact amniotic mem-
branes received amnioinfusion only and four women
with PPROM received amnioinfusion and cerclage. Two
of the four PPROM women who had cerclage suffered
from amniorrhea within 6 hours after amnioinfusion,
and one chose TOP when the fetus was still alive, after
nondirective genetic counseling. The other woman de-
cided to undergo another amnioinfusion and amnio-
patch after thorough discussion. She suffered from
mild amniorrhea on the fourth day after amniopatch,
but her AFI remained at the optimal level for her
gestational age (10). Amniopatch was considered
successful. The mean number of serial amnioinfusions
was 3.9 (range, 1–8) (Table 2).
Intrauterine fetal death (IUFD) was noted in one
treated woman (9.1%) and 11 control women (37.9%).
There was significant prolongation of the latency peri-
od in the treatment group compared with the control
group (34 vs 9 days; p < 0.05) (Table 2). The neonatal
survival rate was also significantly improved in the treat-
ment group compared with the control group (72.7%
vs 20.7%; p < 0.05). The birth weight was greater in the
treatment group than the control group (1,400 vs 900
g; p < 0.05). No women showed signs of infection such
as fever or leukocytosis, but two women in the treat-
ment group (18.2%) and 12 in the control group (41.4%)
developed fever or leukocytosis later. Karyotype was
known and normal in all the women in the treatment
group but for only 20 women in the control group, five
of whom had an abnormal karyotype (Table 1). More
women in the treatment group (9; 81.8%) than control
group (6; 20.7%) had cesarean delivery. The number of
pregnancies whose latency period was more than 21
days was significantly greater in the treatment group
(9) than the control group (0). No serious maternal
complication was noted in any of the subjects. Placental
pathology showed no remarkable findings for any
subjects who underwent this examination (treatment
group, n = 11; control group, n = 27).
Table 1. Demographic and obstetric characteristics
Treatment group (n = 11) Control group (n = 29)
Maternal age, mean (range) (yr)* 32 (23–41)0. 33 (20–43)0.
GA at diagnosis, mean (range) (wk)* 23+2 (17+3–26+0) 23+4 (15+2–29+5)
GA at delivery, mean (range) (wk) 31+3 (24+2–33+4) 26+2 (16+2–30+6)
Fever/leukocytosis at diagnosis* 00 00
PPROM* 4 (36.4%) 13 (44.8%)0.
GA ) 26 wk 11 25
26 wk < GA < 30 wk 00 04
Karyotyping by amniocentesis 04 14
Karyotyping by CVS 03 03
Karyotyping by cordocentesis 04 03
Karyotyping in postnatal period 00 09
Abnormal karyotypes† 00 05
*No significant difference between the two groups; †abnormal karyotypes include 47,XX,+der(2), 45,X, 69,XXY, 47,XY,+21 and 47,XX,+13. CVS = chorionic
villus sampling; GA = gestational age; PPROM = preterm premature rupture of membranes.
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Discussion
Selection bias and matched controls
The difficulty of conducting such a controversial study
rests mainly on the probable selection bias. Some may
argue that the two groups we chose inherited differ-
ent characteristics, which may confound our results.
We tried to match parameters such as maternal age,
gestational age at diagnosis, and the percentage of
PPROM, and excluded confounding factors such as
preexisting infection, fetal/maternal/placental pa-
thology, and patients with the possibility of cervical
incompetence. The major pitfall of this study is that
it was not a randomized controlled trial, and the rea-
sons for offering options in the treatment group and
choosing not to treat in the control group are difficult
to standardize. However, results obtained with ran-
domized and strictly selected groups may have a limited
value in clinical practice since most patients we en-
counter in clinical practice would deviate from such
study groups. We believe our results are of some value
even though this was not a randomized controlled trial.
Furthermore, the prospective nature of our study
enhances its applicability in the real situations en-
countered in practice.
Oligohydramnios
Early onset oligohydramnios is not common and in-
dicates poor fetal prognosis. Apart from PPROM,
the most common etiology is fetal anuria caused by
either obstructive uropathy or renal agenesis. Other
etiologies mainly include maternal disease such as pre-
eclampsia, hypertension, diabetes, hyperthyroidism,
and others [15]. Oligohydramnios is associated with
increased perinatal morbidity and mortality. PPROM
before 25 gestational weeks with severe oligohydram-
nios for more than 14 days has a perinatal mortality of
more than 90% [16]. Maternal chorioamnionitis and
neonatal respiratory distress syndrome are also noted
in more than half of patients [17]. Cerclage and amnio-
infusion were universally offered to patients with
PPROM in the treatment group, which further eliminated
the interaction of both treatment modalities in these
patients.
Amnioinfusion
The efficacy and safety of intrapartum amnioinfusion
have been proven in several prospective randomized
studies, as summarized in an evidence-based meta-
analysis [18]. However, antepartum amnioinfusion is
still under debate, despite its safety and efficacy (in
lengthening the latency between diagnosis and deliv-
ery, in reducing pulmonary hypoplasia, in increasing
diagnostic accuracy of ultrasound, and in reducing
perinatal mortality) reported in some studies [2,7,19,
20]. A large randomized controlled trial is lacking. It is
difficult to study this topic because there are too many
confounding factors such as various underlying fetal/
maternal pathologies and the difficulty controlling for
pregnancy course across many variables. We, therefore,
focused our study on singleton pregnancies complicated
with oligohydramnios, regardless of intact or ruptured
amniotic membranes, and no signs of infection, ob-
serving the latency period and neonatal survival and
maternal infection rates. Other outcome measures such
as birth body weight and the rate of cesarean delivery
were considered unsuitable items for outcome assess-
ment since any conclusion drawn from these markers
may call for considerable speculation and have limited
value.
Table 2. Intervention and delivery characteristics
Treatment group (n = 11) Control group (n = 29)




Amniorrhea < 6 hr after amnioinfusion 02 0
Latency period, mean (range) (d)* 34 (11–59) 9 (2–19)0
Women with latency > 21 d* 09 0
IUFD* 1 (9.1%) 11 (37.9%)0
TOP of viable fetus by induction 1 (9.1%) 12 (41.4%)0
Baby survived > 1 mo* 08 (72.7%) 6 (20.7%)
Birth body weight (g)* 01,400 (350–2,200) 0,900 (190–1,300)
Cesarean delivery 09 (81.8%) 6 (20.7%)
Fever/leukocytosis after diagnosis* 02 (18.2%) 12 (41.4%)0
*p < 0.05. IUFD = intrauterine fetal death; TOP = termination of pregnancy.
Amnioinfusion & Amniopatch for Oligohydramnios
351Taiwanese J Obstet Gynecol • December 2005 • Vol 44 • No 4
Amniopatch
The mechanism of amniopatch is still unclear. The
authors who devised the method speculated that the
platelet/cryoprecipitate plug might seal the amniotic
membranous defect by artificial activation of platelet
and fibrin adhesion at the site of rupture because fetal
membranes are avascular and incapable of eliciting
spontaneous platelet activation, fibrin deposition, and
therefore wound healing. Amniotic membrane is thought
to seal during genetic amniocentesis due to the adher-
ence of amniotic membranes to the underlying chorionic
membranes. Quintero et al documented the detachment
of amniotic membranes from chorionic membranes in
iatrogenic PPROM cases as well as reattachment of
the successful amniopatched cases by ultrasound [13].
Lewi et al documented blood clot in successful amnio-
patched cases with ultrasound [14]. Both groups of
authors considered amniopatch to be more effective
for treating iatrogenic PPROM than spontaneous
PPROM.
Spontaneous PPROM may follow a different natural
history because the hole is usually larger, less demarcated,
and more often situated in the lower uterine segment
than that of iatrogenic PPROM. Amniopatch has been
tried in 11 cases up to 2004 and carries a favorable out-
come when used to treat iatrogenic PPROM [13,14,21,
22]. There were no serious maternal complications in
these 11 women, but IUFD was noted in some cases
[14]. The hypotension and bradycardia induced by
the platelet transfusion, as well as the similar intrinsic
serotonin effect of the indigo carmine used to document
amniorrhea, were thought to be the etiologies [14]. We,
therefore, did not use indigo carmine in our oligohy-
dramnios patients. The good response of the only patient
in our study salvaged with amniopatch seemed a very
rare and interesting success in treating spontaneous
PPROM by amniopatch.
Efficacy and safety of amnioinfusion/amniopatch/
cerclage
In our small series, aggressive management of oligo-
hydramnios, regardless of intact or ruptured amniotic
membranes, seemed to lengthen the latency period
and improve neonatal survival, but not to increase
the rate of maternal infection. Birth weights in the
treatment group seemed to increase more than those
in the control group, while IUFD seemed more fre-
quent in the control group. Our study appears to be
one of the very few reports of amnioinfusion in an East
Asian population [23,24] and of amniopatch world-
wide [13,14,21,22]. The amniopatch case appears to
be the first such successful case reported from East
Asia.
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